These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 21115905)

  • 1. Characterization and evaluation of the antitumour activity of a dual-targeting monoclonal antibody against claudin-3 and claudin-4.
    Kato-Nakano M; Suzuki M; Kawamoto S; Furuya A; Ohta S; Nakamura K; Ando H
    Anticancer Res; 2010 Nov; 30(11):4555-62. PubMed ID: 21115905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers.
    Suzuki M; Kato-Nakano M; Kawamoto S; Furuya A; Abe Y; Misaka H; Kimoto N; Nakamura K; Ohta S; Ando H
    Cancer Sci; 2009 Sep; 100(9):1623-30. PubMed ID: 19555390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel anti-human HB-EGF monoclonal antibody with multiple antitumor mechanisms against ovarian cancer cells.
    Miyamoto S; Iwamoto R; Furuya A; Takahashi K; Sasaki Y; Ando H; Yotsumoto F; Yoneda T; Hamaoka M; Yagi H; Murakami T; Hori S; Shitara K; Mekada E
    Clin Cancer Res; 2011 Nov; 17(21):6733-41. PubMed ID: 21918176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models.
    Chen Y; Clark S; Wong T; Chen Y; Chen Y; Dennis MS; Luis E; Zhong F; Bheddah S; Koeppen H; Gogineni A; Ross S; Polakis P; Mallet W
    Cancer Res; 2007 May; 67(10):4924-32. PubMed ID: 17510422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of delta-like ligand 4 signaling inhibits both growth and angiogenesis of pancreatic cancer.
    Oishi H; Sunamura M; Egawa S; Motoi F; Unno M; Furukawa T; Habib NA; Yagita H
    Pancreas; 2010 Aug; 39(6):897-903. PubMed ID: 20182391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
    Mount PF; Sutton VR; Li W; Burgess J; McKEnzie IF; Pietersz GA; Trapani JA
    Cancer Res; 1994 Dec; 54(23):6160-6. PubMed ID: 7954462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic antibodies to human L1CAM: functional characterization and application in a mouse model for ovarian carcinoma.
    Wolterink S; Moldenhauer G; Fogel M; Kiefel H; Pfeifer M; Lüttgau S; Gouveia R; Costa J; Endell J; Moebius U; Altevogt P
    Cancer Res; 2010 Mar; 70(6):2504-15. PubMed ID: 20215505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel anti-CD20 antibody TGLA with enhanced antibody-dependent cell-mediated cytotoxicity mediates potent anti-lymphoma activity.
    Lv M; Lin Z; Qiao C; Gen S; Lang X; Li Y; Feng J; Shen B
    Cancer Lett; 2010 Aug; 294(1):66-73. PubMed ID: 20202740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors.
    Scott AM; Geleick D; Rubira M; Clarke K; Nice EC; Smyth FE; Stockert E; Richards EC; Carr FJ; Harris WJ; Armour KL; Rood J; Kypridis A; Kronina V; Murphy R; Lee FT; Liu Z; Kitamura K; Ritter G; Laughton K; Hoffman E; Burgess AW; Old LJ
    Cancer Res; 2000 Jun; 60(12):3254-61. PubMed ID: 10866319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16.
    Weiner LM; Holmes M; Adams GP; LaCreta F; Watts P; Garcia de Palazzo I
    Cancer Res; 1993 Jan; 53(1):94-100. PubMed ID: 8093231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity.
    Li B; Shi S; Qian W; Zhao L; Zhang D; Hou S; Zheng L; Dai J; Zhao J; Wang H; Guo Y
    Cancer Res; 2008 Apr; 68(7):2400-8. PubMed ID: 18381448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.
    Chan JK; Hamilton CA; Cheung MK; Karimi M; Baker J; Gall JM; Schulz S; Thorne SH; Teng NN; Contag CH; Lum LG; Negrin RS
    Clin Cancer Res; 2006 Mar; 12(6):1859-67. PubMed ID: 16551871
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MORAb-003, a fully humanized monoclonal antibody against the folate receptor alpha, for the potential treatment of epithelial ovarian cancer.
    Kalli KR
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1067-73. PubMed ID: 18058577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions.
    Maruyama-Takahashi K; Shimada N; Imada T; Maekawa-Tokuda Y; Ishii T; Ouchi J; Kusaka H; Miyaji H; Akinaga S; Tanaka A; Shitara K
    Prostate; 2008 May; 68(6):640-50. PubMed ID: 18213631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a humanized anti-CD20 antibody with potent antitumor activity against B-cell lymphoma.
    Wu L; Wang C; Zhang D; Zhang X; Qian W; Zhao L; Wang H; Li B; Guo Y
    Cancer Lett; 2010 Jun; 292(2):208-14. PubMed ID: 20056316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
    Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel mouse monoclonal antibody targeting ErbB2 suppresses breast cancer growth.
    Kawa S; Matsushita H; Ohbayashi H; Semba K; Yamamoto T
    Biochem Biophys Res Commun; 2009 Jul; 384(3):329-33. PubMed ID: 19409371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of two new monoclonal antibodies reactive to a surface antigen present on human ovarian epithelial cancer cells.
    Xu FJ; Yu YH; Li BY; Moradi M; Elg S; Lane C; Carson L; Ramakrishnan S
    Cancer Res; 1991 Aug; 51(15):4012-9. PubMed ID: 1855217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
    de Weers M; Tai YT; van der Veer MS; Bakker JM; Vink T; Jacobs DC; Oomen LA; Peipp M; Valerius T; Slootstra JW; Mutis T; Bleeker WK; Anderson KC; Lokhorst HM; van de Winkel JG; Parren PW
    J Immunol; 2011 Feb; 186(3):1840-8. PubMed ID: 21187443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
    Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.